Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pro-RAPID
2023-507352-72-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease and indeterminate colitis (IC), sponsored by Erasmus MC. Primary endpoint: Proportion of patients with infliximab trough level ≥ 5 µg/mL at week 12 without treatment escalation. Planned start May 2024; status: authorised.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseindeterminate colitis (IC)
Beyond the preview
Go deeper on 2023-507352-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507352-72-00.